Trial Profile
A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukaemia (CMML)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2022
Price :
$35
*
At a glance
- Drugs Tefinostat (Primary)
- Indications Chronic myelomonocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms MONOCLE
- 04 Dec 2018 Results (n=21) assessing safety and efficacy of Tefinostat in Chronic Myelomonocytic Leukemia (CMML) patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 23 Oct 2018 Planned number of patients has been changed from 40 to 20 as there were an insufficient number of objective clinical responses seen in part 1 of the study to reach the threshold required to trigger the opening of part 2. Therefore the trial never opened to the second stage and did not fulfil the overall study recruitment target of 40 patients
- 23 Oct 2018 Planned number of patients changed from 40 to 20.